Table 1. Baseline demographics and clinical characteristics of patients (n=769).

SD, standard deviation; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; Valsartan, Val; Amlodipine, Aml

Variables		n	%
Gender	Male	315	41.0
	Female	454	59.0
Age	Mean, SD	52.01	± 11.2
Duration of previous treatment, months	Mean, SD	39.23	± 45.4
	ACE inhibitors	85	11.1
	ARBs	110	14.3
	Calcium channel blockers	162	21.1
	Beta blockers	99	12.9
	Alpha blockers	1	0.1
	Diuretics	183	23.9
	Multiple drugs	127	16.6
Co-morbidities	Patient with co-morbidities            (n=353)
	Obesity	101	28.6
	Diabetes mellitus	71	20.1
	Chronic kidney disease	9	2.5
	Chronic heart disease	8	2.3
	Angina	9	2.5
	Previous myocardial infarction	2	0.6
	Recurrent stroke	2	0.6
	Peripheral vascular disease	1	0.3
	Multiple co-morbidities	150	42.5
Initial dose of patients	80/5 mg tablet (80 mg of Val and 5 mg of Aml)	569	73.9
	160/5 mg tablet (160 mg of Val and 5 mg of Aml)	129	16.7
	160/10 mg tablet (160 mg of Val and 10 mg of Aml)	71	9.23